About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Drug Regulators Need To Think In Long-Term, Say Charities

by Medindia Content Team on June 22, 2006 at 9:08 AM
Font : A-A+

Drug Regulators Need To Think In Long-Term, Say Charities

Medical charities have urged drug regulators in Scotland to think in terms of long-term benefit before deciding which drugs are expensive and which are not.

Clara MacKay, of Breast Cancer Care Scotland cited the example of some women needing to take legal recourse for getting Herceptin, the breast cancer drug. "The perception is that those wanting Herceptin are taking away resources. They were demonized for trying to access treatment. Meanwhile the overall picture is ignored," she said.

Advertisement

Herceptin costs approximately 20,000 per year per patient and it is estimated that only around 300 women will receive the drug after costs, which will come up to almost 7.7 million. Mark Hazelwood, director of the Multiple Sclerosis Society Scotland, said that patients should be taken into confidence before any decisions were made.

"Patients don't see access to drugs in isolation. They see the total picture. Drug companies want to rush things through and get a patent but MS is lifelong. We need to capture health costs not just in payment but in its impact on society," he said.

Advertisement

Advertisement
Advertisement

Recommended Reading

Latest Drug News

 India's First Urinary Incontinence Drug Launched
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
 New Ray of Hope for Atrial Fibrillation Patients With Kidney Disease
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Anti-viral Drug Bulevirtide Helps Treat Chronic Hepatitis D
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Antiviral Drug Paxlovid Linked to Lower Risk of Hospital Admission
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Price Cap Move Will Place Eli Lilly Strongly in Insulin Market
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Drug Regulators Need To Think In Long-Term, Say Charities Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests